NEW YORK (GenomeWeb News) – Theradiag said today that it has received the CE Mark for two new biotherapy monitoring kits: tocilizumab and rituximab. Tocilizumab is an immunosuppressive drug used to treat rheumatoid arthritis and juvenile idiopathic arthritis, while rituximab is prescribed for treatment of leukemia and lymphoma. The Theradiag kits are sold under the Lisa Tracker brand name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.